Agios Pharmaceuticals, Inc. Aktie News

Agios Pharmaceuticals, Inc. ( AGIO ) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease November 19, 2025 8:00 AM EST Company Participants Morgan Sanford Brian Goff - CEO & Director Sarah Gheuens - Chief Medical Officer and Head of Research & Development Tsveta Milanova - Chief Commercial Officer Conference Call Participants Biree Andemariam Eric Schmidt - ...

Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026.

Agios Pharmaceuticals stock shed about half its value Wednesday after the company's sickle cell disease treatment lagged expectations.

Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction in pain crises.

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoint of annualized rate of SCPCs (pain crises), and the key secondary endpoint of change from baseline in PROMIS Fatigue was not met Patients in the ...

Agios Pharmaceuticals delivered strong Q3'25 results, with revenue up 44% year-over-year and continued momentum in its rare-disease pipeline. AGIO's key catalysts include the FDA decision on Pyrukynd's thalassemia sNDA in December 2025 and topline data from the 'RISE UP' sickle cell trial. Despite premium valuation, the company maintains a robust balance sheet and is positioned for significant ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate kinase (PK) activator, will be featured in oral and poster presentations during the 67th American Society of Hematology...

Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Morgan Sanford Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Al...